BAP Pharma
BAP Pharma is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)
Sponsor Dompe' Farmaceutici S.p.A.
- Start (EU)
- Latest update
- Estimated end
Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).
Sponsor Dompe' Farmaceutici S.p.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
Sponsor Janssen Vaccines & Prevention B.V.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for BAP Pharma?
The 2026-10-09 snapshot links BAP Pharma to 3 distinct CTIS trials. Recorded services include Medicinal product management, Secondary packaging, labelling, release and distribution. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for BAP Pharma?
The most frequently recorded therapeutic areas are Neurology, Ophthalmology, Trauma and Injury. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to BAP Pharma conducted?
The linked trials record locations in 12 countries, including Poland, Germany, Spain, France, Italy. These are trial locations, not confirmed office locations or countries where BAP Pharma delivered services.
What can this page tell me about BAP Pharma's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under BAP Pharma. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- BAP Pharma GmbH
- Bap Pharma Limited